Concepedia

Author

Christoph Boss

Actelion (Switzerland)ORCID

Also Known As

C. Boss, Christoph B. Olivier (1888528), Christoph Boss, Christoph Boss (1288764), Lorenza Wyder

80

Publications

2.2K

Citations

25

H-Index

43

Concepts

All Affiliations

Actelion (Switzerland)Idorsia (Switzerland)Swiss Tropical and Public Health InstituteUniversity of BaselNational Institutes of Health
CB

About

Christoph Boss is an author at Actelion (Switzerland) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

21

731

2

Biochemistry

11

11

439

3

Natural Sciences

8

8

381

4

Social Sciences

2

2

121

5

Biomolecular Engineering

1

1

26

Christoph Boss

×

33

Publications

1.7K

Citations

21

H-Index

YearCitations

Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

Marc Iglarz, Christoph A. Binkert, Keith Morrison,

Journal of Pharmacology and Experimental Therapeutics

2008

320

Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study

Phillip Scheinberg, C. O. Wu, Óscar Núñez,

Haematologica

2009

158

The Discovery of <i>N</i>-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-<i>N</i>′-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist

Martin H. Bolli, Christoph Boss, Christoph A. Binkert,

Journal of Medicinal Chemistry

2012

146

Discovery and Characterization of ACT‐335827, an Orally Available, Brain Penetrant Orexin Receptor Type 1 Selective Antagonist

Michel A. Steiner, John Gatfield, Catherine Brisbare‐Roch,

ChemMedChem

2013

94

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

Georg Aue, Ndegwa Njuguna, Xin Tian,

Haematologica

2009

93

X-ray Structure of Plasmepsin II Complexed with a Potent Achiral Inhibitor

Lars Prade, Andrew F. Jones, Christoph Boss,

Journal of Biological Chemistry

2005

92

The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468

Alexander Treiber, Ruben de Kanter, Catherine Roch,

Journal of Pharmacology and Experimental Therapeutics

2017

81

Novel Benzo[1,4]diazepin-2-one Derivatives as Endothelin Receptor Antagonists

Martin H. Bolli, Judith Marfurt, Corinna Grisostomi,

Journal of Medicinal Chemistry

2004

76

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling

Amélie Le Bihan, Ruben de Kanter, Íñigo Angulo‐Barturen,

PLoS Medicine

2016

69

Achiral, Cheap, and Potent Inhibitors of Plasmepsins I, II, and IV

Christoph Boss, Olivier Corminboeuf, Corinna Grisostomi,

ChemMedChem

2006

53

Page 1